EWCZ vs REGN vs BIIB vs FAT

For growth investors, FAT Brands Inc.

(FAT) is the stronger pick with 23. 4% revenue growth year-over-year, versus -1. 9% for European Wax Center, Inc. (EWCZ). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus European Wax Center, Inc. at 26. 5x. On forward P/E, European Wax Center, Inc. is actually cheaper at 8. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Regeneron Pharmaceuticals, Inc.

(REGN) delivered a total return of +43. 6%, compared to -57. 4% for European Wax Center, Inc. (EWCZ). Over 10 years, the gap is even starker: REGN returned +90. 0% versus EWCZ's -57. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 64β versus FAT Brands Inc. 's 1. 56β — meaning FAT is approximately 144% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 4% for European Wax Center, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), FAT Brands Inc.

(FAT) is pulling ahead at 23. 4% versus -1. 9% for European Wax Center, Inc. (EWCZ). On earnings-per-share growth, the picture is similar: European Wax Center, Inc. grew EPS 29. 4% year-over-year, compared to -98. 3% for FAT Brands Inc.. Over a 3-year CAGR, FAT leads at 70. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -32. 0% for FAT Brands Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -8. 8% for FAT. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, European Wax Center, Inc.

(EWCZ) trades at 8. 5x forward P/E versus 15. 3x for Regeneron Pharmaceuticals, Inc. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REGN: 22. 1% to $865. 68.

In this comparison, FAT (100.

0% yield), REGN (0. 5% yield), EWCZ (0. 3% yield) pay a dividend. BIIB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Biogen Inc.

(BIIB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 64)). Both have compounded well over 10 years (BIIB: -29. 2%, EWCZ: -57. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EWCZ (Consumer Defensive) and REGN (Healthcare) and BIIB (Healthcare) and FAT (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EWCZ is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock; BIIB is a mid-cap quality compounder stock; FAT is a small-cap high-growth stock. FAT pays a dividend while EWCZ, REGN, BIIB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.